Invention Grant
US08907087B2 Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors
有权
取代的吡嗪并[2,3-b]吡嗪作为mTOR激酶抑制剂
- Patent Title: Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors
- Patent Title (中): 取代的吡嗪并[2,3-b]吡嗪作为mTOR激酶抑制剂
-
Application No.: US13927255Application Date: 2013-06-26
-
Publication No.: US08907087B2Publication Date: 2014-12-09
- Inventor: Sophie Perrin-Ninkovic , Roy L. Harris , John Sapienza , Graziella I. Shevlin , Patrick Papa , Branden Lee , Garrick Packard , Jingjing Zhao , Jennifer Riggs , Jason Parnes , Deborah Mortensen , Jan Elsner
- Applicant: Signal Pharmaceuticals, LLC
- Applicant Address: US CA San Diego
- Assignee: Signal Pharmaceuticals, LLC
- Current Assignee: Signal Pharmaceuticals, LLC
- Current Assignee Address: US CA San Diego
- Agency: Jones Day
- Main IPC: C07D241/38
- IPC: C07D241/38 ; C07D498/14 ; C07D487/04
![Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors](/abs-image/US/2014/12/09/US08907087B2/abs.jpg.150x150.jpg)
Abstract:
Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof. Furthermore, provided are methods of preparing a compound of formula (III), Furthermore, provided are methods of preparing a compound of formula (VI),
Public/Granted literature
Information query